Newron H1 FY26 net loss widens to EUR 16.4 million; revenue drops 73.2% to EUR 3.2 million

(AWP Alliance News) - Newron Pharmaceuticals reported H1 2026 revenue of EUR 3.19 million, down 73.2% from a year earlier. Net loss widened to EUR 16.37 million, while R&D expenses climbed to EUR 14.55 million. Cash and other current financial assets totaled EUR 32.89 million at June 30, 2026, up from EUR 28.88 million at end-2025. The group said screening in its Phase 3 ENIGMA-TRS 1 evenamide study was completed in September, with target enrollment of at least 600 patients expected around mid-October and topline 12-week results due in Q1 2027. CEO Stefan Weber said the company expects U.S. enrollment in ENIGMA-TRS 2 to resume in the near future following a Type A meeting with the FDA in July.

https://docs.publicnow.com/658E610EBD6E940D07E514990876A08D7317F87B

Disclaimer: This news brief was created using generative artificial intelligence. Newron Pharmaceuticals S.p.A. published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.